These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31321581)

  • 1. Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients.
    Otagaki M; Matsumura K; Kin H; Fujii K; Shibutani H; Matsumoto H; Takahashi H; Park H; Yamamoto Y; Sugiura T; Shiojima I
    Cardiovasc Drugs Ther; 2019 Aug; 33(4):435-442. PubMed ID: 31321581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus.
    Ikeda S; Takano Y; Schwab D; Portron A; Kasahara-Ito N; Saito T; Iida S
    Drug Res (Stuttg); 2019 Jun; 69(6):314-322. PubMed ID: 30103216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
    Bekki M; Tahara N; Tahara A; Igata S; Honda A; Sugiyama Y; Nakamura T; Sun J; Kumashiro Y; Matsui T; Fukumoto Y; Yamagishi SI
    Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Tofogliflozin on Physiological and Hormonal Function, Serum Electrolytes, and Cardiac Diastolic Function in Elderly Japanese Patients with Type 2 Diabetes Mellitus.
    Higashikawa T; Ito T; Mizuno T; Ishigami K; Kuroki K; Maekawa N; Usuda D; Izumida T; Yamada S; Sangen R; Hamada K; Kiyosawa J; Saito A; Iguchi M; Kasamaki Y; Nakahashi T; Fukuda A; Saito H; Kanda T; Okuro M
    Acta Med Okayama; 2022 Dec; 76(6):705-713. PubMed ID: 36549773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
    Kasahara N; Fukase H; Ohba Y; Saito T; Miyata K; Iida S; Takano Y; Ikeda S; Harigai M; Terao K
    Drug Res (Stuttg); 2016 Feb; 66(2):74-81. PubMed ID: 26158794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study.
    Katakami N; Mita T; Yoshii H; Shiraiwa T; Yasuda T; Okada Y; Torimoto K; Umayahara Y; Kaneto H; Osonoi T; Yamamoto T; Kuribayashi N; Maeda K; Yokoyama H; Kosugi K; Ohtoshi K; Hayashi I; Sumitani S; Tsugawa M; Ryomoto K; Taki H; Nakamura T; Kawashima S; Sato Y; Watada H; Shimomura I;
    Cardiovasc Diabetol; 2020 Jul; 19(1):110. PubMed ID: 32646498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of sodium-glucose cotransporter 2 inhibitor (tofogliflozin) on renal tubular damage in diabetic patients without albuminuria.
    Shimohata H; Iwaki Y; Yamashita M; Ohgi K; Maruyama H; Takayasu M; Hirayama K; Kobayashi M
    Int Urol Nephrol; 2022 Aug; 54(8):1907-1914. PubMed ID: 34843041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and Design of Prospective, Multicenter, Double-Arm Clinical Trial to Investigate the Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus (TOP-HFPEF Trial).
    Ito S; Nakajima Y; Fukuda H; Izumi C; Nakazawa G; Yamashita H; Matsuhisa H; Inoko M; Toyoda S; Takiuchi S; Kataoka T; Izumiya Y; Abe Y; Sozu T; Sakata Y; Emoto M; Inoue T; Kitakaze M
    Cardiovasc Drugs Ther; 2024 May; ():. PubMed ID: 38727896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory Effects of Tofogliflozin on Cardiac Hypertrophy in Dahl Salt-Sensitive and Salt-Resistant Rats Fed a High-Fat Diet.
    Kimura T; Nakamura K; Miyoshi T; Yoshida M; Akazawa K; Saito Y; Akagi S; Ohno Y; Kondo M; Miura D; Wada J; Ito H
    Int Heart J; 2019 May; 60(3):728-735. PubMed ID: 31105148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall-a sub-analysis of the UTOPIA trial.
    Katakami N; Mita T; Maeda N; Sato Y; Watada H; Shimomura I;
    Cardiovasc Diabetol; 2022 Feb; 21(1):19. PubMed ID: 35123483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The sodium-glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice.
    Li Z; Murakoshi M; Ichikawa S; Koshida T; Adachi E; Suzuki C; Ueda S; Gohda T; Suzuki Y
    FEBS Open Bio; 2020 Dec; 10(12):2761-2770. PubMed ID: 33098615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sodium-glucose co-transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE-deficient mice with streptozotocin-induced diabetes.
    Iwamoto M; Kubota T; Sakurai Y; Wada N; Shioda S; Yamauchi T; Kadowaki T; Kubota N
    Pharmacol Res Perspect; 2022 Aug; 10(4):e00971. PubMed ID: 35707828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.
    Suzuki M; Honda K; Fukazawa M; Ozawa K; Hagita H; Kawai T; Takeda M; Yata T; Kawai M; Fukuzawa T; Kobayashi T; Sato T; Kawabe Y; Ikeda S
    J Pharmacol Exp Ther; 2012 Jun; 341(3):692-701. PubMed ID: 22410641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Tofogliflozin on Cardiac Function in Elderly Patients With Diabetes Mellitus.
    Higashikawa T; Ito T; Mizuno T; Ishigami K; Kohori M; Mae K; Usuda D; Takagi S; Sangen R; Saito A; Iguchi M; Kasamaki Y; Fukuda A; Kanda T; Okuro M
    J Clin Med Res; 2020 Mar; 12(3):165-171. PubMed ID: 32231752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor.
    Kurozumi A; Okada Y; Shimokawa M; Goshima Y; Otsuka T; Narisawa M; Torimoto K; Tanaka Y
    Diabetes Technol Ther; 2019 Jul; 21(7):385-392. PubMed ID: 31210529
    [No Abstract]   [Full Text] [Related]  

  • 16. The Effect of Sodium-Dependent Glucose Cotransporter 2 Inhibitor Tofogliflozin on Neurovascular Coupling in the Retina in Type 2 Diabetic Mice.
    Hanaguri J; Yokota H; Kushiyama A; Kushiyama S; Watanabe M; Yamagami S; Nagaoka T
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Dapagliflozin on the Left Ventricular Diastolic Function in Diabetic Patients with Heart Failure Complicating Cardiovascular Risk Factors.
    Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
    Intern Med; 2021; 60(15):2367-2374. PubMed ID: 34334588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction.
    Connelly KA; Zhang Y; Desjardins JF; Thai K; Gilbert RE
    Cardiovasc Diabetol; 2018 Jul; 17(1):99. PubMed ID: 29981571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Sodium Glucose Cotransporter 2 Inhibitor Fails to Improve Perivascular Adipose Tissue-Mediated Modulation of Vasodilation and Cardiac Function in Rats With Metabolic Syndrome.
    Kagota S; Maruyama-Fumoto K; McGuire JJ; Shinozuka K
    J Cardiovasc Pharmacol Ther; 2021 Sep; 26(5):480-489. PubMed ID: 33764804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes.
    Lan NSR; Yeap BB; Fegan PG; Green G; Rankin JM; Dwivedi G
    Int J Cardiovasc Imaging; 2021 Feb; 37(2):517-527. PubMed ID: 32959096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.